Michele Fox
Concepts (437)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 31 | 2023 | 577 | 2.220 |
Why?
| Hematopoietic Stem Cells | 21 | 2018 | 197 | 1.930 |
Why?
| Multiple Myeloma | 44 | 2024 | 2998 | 1.830 |
Why?
| Bone Marrow Transplantation | 27 | 2016 | 136 | 1.790 |
Why?
| Hematopoietic Stem Cell Mobilization | 13 | 2018 | 58 | 1.440 |
Why?
| Antigens, CD34 | 20 | 2018 | 75 | 0.980 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 1000 | 0.900 |
Why?
| Cell Separation | 8 | 2013 | 92 | 0.810 |
Why?
| Blood Platelets | 5 | 2017 | 251 | 0.800 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 3 | 2018 | 16 | 0.720 |
Why?
| Melphalan | 7 | 2016 | 178 | 0.610 |
Why?
| Leukapheresis | 5 | 2018 | 17 | 0.590 |
Why?
| Transplantation, Autologous | 21 | 2013 | 481 | 0.580 |
Why?
| Fetal Blood | 4 | 2023 | 66 | 0.580 |
Why?
| Myelodysplastic Syndromes | 3 | 2013 | 78 | 0.550 |
Why?
| Graft vs Host Disease | 15 | 2003 | 84 | 0.520 |
Why?
| Leukocytes, Mononuclear | 5 | 2018 | 118 | 0.500 |
Why?
| Plasma Exchange | 3 | 2015 | 25 | 0.490 |
Why?
| Humans | 89 | 2024 | 50578 | 0.480 |
Why?
| Adult | 47 | 2019 | 13604 | 0.450 |
Why?
| Middle Aged | 42 | 2018 | 12615 | 0.440 |
Why?
| Flow Cytometry | 6 | 2016 | 474 | 0.420 |
Why?
| Aged | 32 | 2017 | 9747 | 0.410 |
Why?
| Transplantation Conditioning | 9 | 2006 | 87 | 0.400 |
Why?
| Granulocyte Colony-Stimulating Factor | 7 | 2012 | 63 | 0.390 |
Why?
| Killer Cells, Natural | 3 | 2015 | 106 | 0.390 |
Why?
| Pregnant Women | 1 | 2023 | 74 | 0.390 |
Why?
| Blood Component Removal | 4 | 2018 | 10 | 0.390 |
Why?
| Female | 49 | 2023 | 27148 | 0.370 |
Why?
| Chromosome Aberrations | 5 | 2016 | 280 | 0.360 |
Why?
| Cell Proliferation | 5 | 2018 | 985 | 0.350 |
Why?
| Male | 46 | 2019 | 25923 | 0.350 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 163 | 0.340 |
Why?
| Transplantation, Homologous | 13 | 2016 | 145 | 0.340 |
Why?
| Platelet Count | 4 | 2017 | 65 | 0.340 |
Why?
| Antigens, CD | 10 | 2003 | 222 | 0.330 |
Why?
| Blood Transfusion | 3 | 2017 | 129 | 0.330 |
Why?
| Thalidomide | 5 | 2016 | 378 | 0.330 |
Why?
| Blood Specimen Collection | 1 | 2019 | 35 | 0.320 |
Why?
| Antibodies | 2 | 2016 | 153 | 0.320 |
Why?
| Blood Volume | 1 | 2019 | 69 | 0.310 |
Why?
| Education, Distance | 1 | 2019 | 42 | 0.310 |
Why?
| Erythrocyte Transfusion | 3 | 2015 | 52 | 0.300 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 28 | 0.300 |
Why?
| Cryopreservation | 3 | 2010 | 33 | 0.300 |
Why?
| Lymphoma | 3 | 2018 | 67 | 0.290 |
Why?
| Obstetrics | 1 | 2019 | 86 | 0.290 |
Why?
| Leukemia | 3 | 2013 | 65 | 0.290 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2017 | 38 | 0.280 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 5 | 0.280 |
Why?
| Blood Coagulation | 1 | 2017 | 60 | 0.280 |
Why?
| Leukocytes | 3 | 2011 | 69 | 0.270 |
Why?
| Bone Marrow Cells | 5 | 2004 | 196 | 0.270 |
Why?
| Graft Survival | 7 | 2011 | 159 | 0.270 |
Why?
| Follow-Up Studies | 11 | 2024 | 2243 | 0.270 |
Why?
| Aspirin | 1 | 2017 | 112 | 0.260 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 121 | 0.260 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2000 | 45 | 0.260 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 174 | 0.250 |
Why?
| Combined Modality Therapy | 12 | 2014 | 641 | 0.240 |
Why?
| Hemoglobins, Abnormal | 1 | 2015 | 4 | 0.240 |
Why?
| Heparin | 1 | 2015 | 91 | 0.240 |
Why?
| Thrombocytopenia | 1 | 2015 | 81 | 0.240 |
Why?
| Stem Cell Transplantation | 2 | 2013 | 179 | 0.240 |
Why?
| Factor VIII | 1 | 2014 | 23 | 0.230 |
Why?
| ADAM Proteins | 1 | 2014 | 20 | 0.230 |
Why?
| Methotrexate | 2 | 2001 | 72 | 0.230 |
Why?
| Anemia, Sickle Cell | 1 | 2015 | 94 | 0.220 |
Why?
| Cancer Vaccines | 3 | 2010 | 80 | 0.220 |
Why?
| Internship and Residency | 1 | 2019 | 447 | 0.220 |
Why?
| Dendritic Cells | 3 | 2010 | 135 | 0.210 |
Why?
| Prognosis | 8 | 2018 | 1978 | 0.210 |
Why?
| Retroviridae | 4 | 1997 | 9 | 0.210 |
Why?
| Retrospective Studies | 11 | 2018 | 6272 | 0.210 |
Why?
| Neoplasm Recurrence, Local | 3 | 2015 | 629 | 0.210 |
Why?
| Cell Count | 7 | 2011 | 150 | 0.210 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 32 | 0.210 |
Why?
| Cytomegalovirus Infections | 3 | 2001 | 38 | 0.210 |
Why?
| Cell Survival | 7 | 2011 | 589 | 0.200 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.200 |
Why?
| Bone Marrow | 8 | 1997 | 363 | 0.200 |
Why?
| Dexamethasone | 6 | 2024 | 432 | 0.200 |
Why?
| Graft vs Tumor Effect | 2 | 2006 | 3 | 0.200 |
Why?
| Treatment Outcome | 19 | 2013 | 5284 | 0.190 |
Why?
| Leukemia, Myeloid | 2 | 2000 | 44 | 0.190 |
Why?
| Adenoviridae Infections | 1 | 2001 | 3 | 0.190 |
Why?
| Aldehyde Dehydrogenase | 1 | 2011 | 25 | 0.190 |
Why?
| Gene Transfer Techniques | 3 | 1997 | 41 | 0.190 |
Why?
| Lung Diseases, Fungal | 1 | 2001 | 19 | 0.190 |
Why?
| Tamoxifen | 1 | 2001 | 60 | 0.190 |
Why?
| Cyclophosphamide | 8 | 2006 | 168 | 0.180 |
Why?
| Boronic Acids | 2 | 2013 | 183 | 0.180 |
Why?
| Pyrazines | 2 | 2013 | 188 | 0.180 |
Why?
| Plateletpheresis | 1 | 2010 | 7 | 0.180 |
Why?
| Blood Preservation | 1 | 2010 | 26 | 0.180 |
Why?
| Lymphoma, B-Cell | 1 | 2000 | 49 | 0.170 |
Why?
| Immunosuppressive Agents | 4 | 2014 | 225 | 0.170 |
Why?
| Blood Proteins | 1 | 2010 | 84 | 0.170 |
Why?
| Myeloablative Agonists | 3 | 2007 | 32 | 0.170 |
Why?
| Fever | 1 | 2001 | 112 | 0.170 |
Why?
| Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 56 | 0.170 |
Why?
| Anaphylaxis | 1 | 2010 | 69 | 0.170 |
Why?
| Genetic Vectors | 4 | 1997 | 128 | 0.160 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2007 | 92 | 0.160 |
Why?
| Blood Cells | 4 | 1994 | 47 | 0.160 |
Why?
| Incidence | 7 | 2017 | 1032 | 0.160 |
Why?
| HIV Infections | 1 | 2013 | 352 | 0.160 |
Why?
| Receptors, KIR | 1 | 2008 | 13 | 0.160 |
Why?
| Etoposide | 6 | 2006 | 77 | 0.160 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 833 | 0.150 |
Why?
| Disease-Free Survival | 6 | 2016 | 444 | 0.150 |
Why?
| Cell Movement | 2 | 2006 | 247 | 0.140 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 23 | 0.140 |
Why?
| Immunoglobulins, Intravenous | 3 | 1992 | 65 | 0.140 |
Why?
| Lymphocyte Transfusion | 3 | 2003 | 12 | 0.140 |
Why?
| Risk Factors | 7 | 2015 | 3724 | 0.130 |
Why?
| Breast Neoplasms | 6 | 1995 | 1200 | 0.130 |
Why?
| Models, Genetic | 1 | 2006 | 172 | 0.130 |
Why?
| Osteogenesis | 2 | 2006 | 356 | 0.130 |
Why?
| Transformation, Genetic | 1 | 1995 | 18 | 0.130 |
Why?
| Models, Statistical | 1 | 2007 | 226 | 0.130 |
Why?
| Antineoplastic Agents | 5 | 2012 | 1172 | 0.130 |
Why?
| Young Adult | 4 | 2019 | 4113 | 0.130 |
Why?
| Time Factors | 2 | 2010 | 2939 | 0.120 |
Why?
| Cytokines | 2 | 2006 | 606 | 0.120 |
Why?
| Gene Expression Profiling | 2 | 2007 | 1025 | 0.120 |
Why?
| Macrophages | 1 | 2018 | 364 | 0.120 |
Why?
| Metaphase | 3 | 2016 | 45 | 0.120 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 1995 | 76 | 0.120 |
Why?
| Dimethyl Sulfoxide | 2 | 2010 | 13 | 0.120 |
Why?
| Recurrence | 4 | 2008 | 659 | 0.120 |
Why?
| Mycobacterium tuberculosis | 1 | 2007 | 266 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 234 | 0.120 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 1995 | 125 | 0.120 |
Why?
| Models, Biological | 2 | 2007 | 716 | 0.120 |
Why?
| Risk | 2 | 2017 | 324 | 0.120 |
Why?
| Immunoglobulin G | 3 | 2003 | 190 | 0.120 |
Why?
| Acute Disease | 4 | 2013 | 373 | 0.120 |
Why?
| Postoperative Complications | 2 | 2001 | 1034 | 0.110 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 1995 | 158 | 0.110 |
Why?
| Pregnancy | 2 | 2023 | 2504 | 0.110 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 2016 | 27 | 0.110 |
Why?
| Blood Banks | 1 | 2023 | 17 | 0.110 |
Why?
| Sweet Syndrome | 1 | 2003 | 11 | 0.110 |
Why?
| Neoplasms | 4 | 2007 | 1252 | 0.100 |
Why?
| Bone Diseases | 1 | 2004 | 96 | 0.100 |
Why?
| Osteoblasts | 1 | 2006 | 462 | 0.100 |
Why?
| Cyclosporine | 1 | 2003 | 66 | 0.100 |
Why?
| Prospective Studies | 6 | 2016 | 2383 | 0.100 |
Why?
| Tacrolimus | 1 | 2003 | 53 | 0.100 |
Why?
| Hemorrhage | 2 | 2017 | 197 | 0.100 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 5 | 0.100 |
Why?
| ABO Blood-Group System | 1 | 2002 | 15 | 0.100 |
Why?
| Universities | 1 | 2023 | 170 | 0.100 |
Why?
| T-Lymphocytes | 2 | 1998 | 325 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2007 | 464 | 0.100 |
Why?
| Coculture Techniques | 3 | 2018 | 142 | 0.100 |
Why?
| Ovarian Neoplasms | 1 | 1995 | 450 | 0.090 |
Why?
| Genetic Therapy | 3 | 1995 | 120 | 0.090 |
Why?
| Lymphoma, Mantle-Cell | 2 | 2001 | 14 | 0.090 |
Why?
| Cryoprotective Agents | 2 | 1998 | 8 | 0.090 |
Why?
| Hodgkin Disease | 2 | 2002 | 47 | 0.090 |
Why?
| Osteoclasts | 1 | 2004 | 427 | 0.090 |
Why?
| Platelet Transfusion | 2 | 2010 | 29 | 0.090 |
Why?
| Lymphocyte Depletion | 3 | 1996 | 9 | 0.090 |
Why?
| Tissue Preservation | 2 | 1998 | 8 | 0.090 |
Why?
| Cyclosporins | 2 | 1991 | 11 | 0.090 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2012 | 56 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 63 | 0.090 |
Why?
| Tissue Donors | 3 | 2003 | 121 | 0.080 |
Why?
| Heart Failure | 1 | 2006 | 528 | 0.080 |
Why?
| Thrombosis | 1 | 2003 | 250 | 0.080 |
Why?
| Vaccines, DNA | 1 | 1999 | 12 | 0.080 |
Why?
| Erythroid Precursor Cells | 1 | 2019 | 15 | 0.080 |
Why?
| Logistic Models | 3 | 2017 | 899 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2017 | 1203 | 0.080 |
Why?
| Cisplatin | 4 | 2006 | 286 | 0.080 |
Why?
| Birth Weight | 1 | 2019 | 106 | 0.080 |
Why?
| Graft vs Host Reaction | 1 | 1998 | 1 | 0.080 |
Why?
| Antigens, Neoplasm | 2 | 2005 | 148 | 0.080 |
Why?
| Hematocrit | 1 | 2018 | 43 | 0.070 |
Why?
| Survival Analysis | 6 | 2006 | 661 | 0.070 |
Why?
| Salvage Therapy | 3 | 2003 | 137 | 0.070 |
Why?
| Medical Waste | 1 | 2017 | 2 | 0.070 |
Why?
| Cell Aggregation | 1 | 2017 | 6 | 0.070 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2008 | 73 | 0.070 |
Why?
| Neutrophils | 2 | 2006 | 145 | 0.070 |
Why?
| Program Evaluation | 1 | 2019 | 350 | 0.070 |
Why?
| Arkansas | 2 | 2017 | 1991 | 0.070 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 21 | 0.070 |
Why?
| Neoplasm Proteins | 2 | 2016 | 320 | 0.070 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 46 | 0.070 |
Why?
| Lymphocyte Activation | 2 | 1995 | 164 | 0.070 |
Why?
| Antibodies, Monoclonal | 2 | 2002 | 462 | 0.070 |
Why?
| Infant, Newborn | 2 | 2019 | 2768 | 0.070 |
Why?
| Fibrosis | 1 | 2017 | 181 | 0.070 |
Why?
| Adolescent | 5 | 2015 | 6447 | 0.070 |
Why?
| Reticulocyte Count | 1 | 2006 | 5 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1372 | 0.060 |
Why?
| Tumor Escape | 1 | 2006 | 17 | 0.060 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 90 | 0.060 |
Why?
| Curriculum | 1 | 2019 | 400 | 0.060 |
Why?
| Mice | 5 | 2018 | 5687 | 0.060 |
Why?
| Prostatic Neoplasms | 1 | 1999 | 384 | 0.060 |
Why?
| Glucosylceramidase | 1 | 1995 | 9 | 0.060 |
Why?
| Membrane Glycoproteins | 3 | 2004 | 245 | 0.060 |
Why?
| Cytogenetic Analysis | 2 | 2007 | 74 | 0.060 |
Why?
| Neutropenia | 1 | 2006 | 116 | 0.060 |
Why?
| Hemoglobin J | 1 | 2015 | 3 | 0.060 |
Why?
| Hemoglobin, Sickle | 1 | 2015 | 6 | 0.060 |
Why?
| Hemoglobin C | 1 | 2015 | 6 | 0.060 |
Why?
| Hematologic Neoplasms | 1 | 1996 | 99 | 0.060 |
Why?
| Clinical Protocols | 2 | 2012 | 110 | 0.060 |
Why?
| Blood Donors | 1 | 2015 | 32 | 0.060 |
Why?
| Aged, 80 and over | 3 | 2013 | 3227 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1033 | 0.060 |
Why?
| Cell Line | 2 | 2008 | 988 | 0.060 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2007 | 393 | 0.060 |
Why?
| Animals | 7 | 2018 | 13125 | 0.060 |
Why?
| Base Sequence | 3 | 1995 | 639 | 0.060 |
Why?
| Autoantibodies | 1 | 2014 | 117 | 0.050 |
Why?
| Age Factors | 3 | 2005 | 1111 | 0.050 |
Why?
| Specimen Handling | 1 | 1994 | 55 | 0.050 |
Why?
| Whole-Body Irradiation | 4 | 1998 | 132 | 0.050 |
Why?
| Molecular Sequence Data | 3 | 1995 | 778 | 0.050 |
Why?
| Multivariate Analysis | 3 | 2007 | 583 | 0.050 |
Why?
| Blotting, Western | 1 | 2015 | 578 | 0.050 |
Why?
| Prednisone | 2 | 2000 | 101 | 0.050 |
Why?
| Feasibility Studies | 2 | 2011 | 394 | 0.050 |
Why?
| Interferon-gamma | 2 | 2010 | 177 | 0.050 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 32 | 0.050 |
Why?
| Quality Assurance, Health Care | 1 | 1994 | 150 | 0.050 |
Why?
| Pulmonary Fibrosis | 2 | 1991 | 19 | 0.050 |
Why?
| Viral Load | 1 | 2013 | 76 | 0.050 |
Why?
| Immunization, Passive | 1 | 1992 | 30 | 0.050 |
Why?
| Transplantation Chimera | 3 | 2003 | 14 | 0.050 |
Why?
| Pharmacokinetics | 1 | 1992 | 17 | 0.050 |
Why?
| Cohort Studies | 3 | 2006 | 1456 | 0.050 |
Why?
| Haplotypes | 2 | 2008 | 83 | 0.050 |
Why?
| Bone Marrow Purging | 1 | 1992 | 2 | 0.050 |
Why?
| Infection Control | 1 | 1992 | 47 | 0.050 |
Why?
| Benzylamines | 1 | 2012 | 15 | 0.050 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 30 | 0.050 |
Why?
| Immunoglobulins | 1 | 1992 | 81 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2015 | 957 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2008 | 476 | 0.050 |
Why?
| Heterocyclic Compounds | 1 | 2012 | 29 | 0.050 |
Why?
| Urine | 1 | 1991 | 24 | 0.050 |
Why?
| Kanamycin Kinase | 2 | 1995 | 2 | 0.050 |
Why?
| Carmustine | 1 | 2001 | 14 | 0.050 |
Why?
| Pneumonia, Pneumocystis | 1 | 2001 | 7 | 0.050 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2002 | 55 | 0.050 |
Why?
| Microscopy, Electron | 1 | 2001 | 77 | 0.050 |
Why?
| Child | 5 | 2015 | 6907 | 0.050 |
Why?
| Immune Tolerance | 1 | 2011 | 84 | 0.050 |
Why?
| DNA Primers | 2 | 1995 | 206 | 0.050 |
Why?
| Foscarnet | 1 | 2001 | 2 | 0.050 |
Why?
| Tumor Cells, Cultured | 2 | 1996 | 457 | 0.050 |
Why?
| Ganciclovir | 1 | 2001 | 25 | 0.050 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 7 | 0.050 |
Why?
| Cytomegalovirus | 1 | 2001 | 28 | 0.040 |
Why?
| Fatal Outcome | 1 | 2001 | 197 | 0.040 |
Why?
| Quality Control | 3 | 2005 | 98 | 0.040 |
Why?
| Antigens, Viral | 1 | 2001 | 42 | 0.040 |
Why?
| Chimera | 1 | 1990 | 10 | 0.040 |
Why?
| Isotonic Solutions | 1 | 2010 | 17 | 0.040 |
Why?
| Syndrome | 1 | 2001 | 240 | 0.040 |
Why?
| Anemia, Aplastic | 1 | 1990 | 11 | 0.040 |
Why?
| Neovascularization, Pathologic | 1 | 2001 | 155 | 0.040 |
Why?
| Transfection | 3 | 1999 | 356 | 0.040 |
Why?
| P-Selectin | 1 | 2010 | 32 | 0.040 |
Why?
| Virus Activation | 1 | 2001 | 37 | 0.040 |
Why?
| Sodium Chloride | 1 | 2010 | 55 | 0.040 |
Why?
| Angiogenesis Inhibitors | 2 | 2007 | 183 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2010 | 70 | 0.040 |
Why?
| Algorithms | 2 | 2005 | 631 | 0.040 |
Why?
| Platelet Activation | 1 | 2010 | 45 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2007 | 932 | 0.040 |
Why?
| Hypersensitivity | 1 | 2010 | 75 | 0.040 |
Why?
| Peripheral Nervous System Diseases | 1 | 1990 | 58 | 0.040 |
Why?
| Polyomavirus | 1 | 1989 | 3 | 0.040 |
Why?
| Polymerase Chain Reaction | 2 | 1995 | 449 | 0.040 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2007 | 181 | 0.040 |
Why?
| Antiviral Agents | 1 | 2001 | 170 | 0.040 |
Why?
| Cystitis | 1 | 1989 | 18 | 0.040 |
Why?
| Ultraviolet Rays | 1 | 1989 | 49 | 0.040 |
Why?
| Glucocorticoids | 1 | 2000 | 230 | 0.040 |
Why?
| Carrier Proteins | 2 | 2004 | 298 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 65 | 0.040 |
Why?
| Pilot Projects | 1 | 2000 | 702 | 0.040 |
Why?
| DNA | 1 | 1991 | 535 | 0.040 |
Why?
| Ligands | 1 | 2008 | 203 | 0.040 |
Why?
| Arginase | 1 | 2018 | 37 | 0.040 |
Why?
| Polyethylene Glycols | 1 | 2008 | 86 | 0.040 |
Why?
| Hemoglobins | 1 | 2008 | 109 | 0.040 |
Why?
| Age Distribution | 1 | 2007 | 171 | 0.040 |
Why?
| Theophylline | 1 | 2007 | 20 | 0.030 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.030 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.030 |
Why?
| Chromosome Deletion | 1 | 2007 | 134 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2007 | 231 | 0.030 |
Why?
| Chromosome Mapping | 1 | 2006 | 153 | 0.030 |
Why?
| Apoptosis | 1 | 2001 | 1097 | 0.030 |
Why?
| Benzopyrenes | 1 | 1975 | 2 | 0.030 |
Why?
| 3T3 Cells | 1 | 1995 | 56 | 0.030 |
Why?
| Epithelium | 1 | 1975 | 66 | 0.030 |
Why?
| Cytotoxicity, Immunologic | 1 | 1995 | 55 | 0.030 |
Why?
| Interleukin-2 | 1 | 1995 | 71 | 0.030 |
Why?
| Cell Communication | 1 | 2006 | 68 | 0.030 |
Why?
| Interleukin-10 | 1 | 2006 | 84 | 0.030 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 110 | 0.030 |
Why?
| Liver | 1 | 2001 | 1132 | 0.030 |
Why?
| Life Tables | 2 | 2002 | 9 | 0.030 |
Why?
| Stroke Volume | 1 | 2006 | 141 | 0.030 |
Why?
| Ficoll | 2 | 1996 | 2 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2006 | 114 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2006 | 106 | 0.030 |
Why?
| Databases, Factual | 1 | 2007 | 673 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2006 | 540 | 0.030 |
Why?
| Bromodeoxyuridine | 1 | 2004 | 18 | 0.030 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 33 | 0.030 |
Why?
| Annexin A5 | 1 | 2004 | 14 | 0.030 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 47 | 0.030 |
Why?
| Epithelial Cells | 1 | 1975 | 207 | 0.030 |
Why?
| Immunotherapy | 2 | 2002 | 235 | 0.030 |
Why?
| Phagocytosis | 1 | 2004 | 44 | 0.030 |
Why?
| Survival Rate | 1 | 2006 | 909 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 20 | 0.030 |
Why?
| Syndecans | 1 | 2003 | 37 | 0.030 |
Why?
| Paraproteins | 1 | 2003 | 13 | 0.030 |
Why?
| Cell Division | 1 | 2004 | 291 | 0.030 |
Why?
| Chronic Disease | 1 | 2006 | 574 | 0.030 |
Why?
| Ifosfamide | 2 | 1993 | 11 | 0.030 |
Why?
| Syndecan-1 | 1 | 2003 | 75 | 0.030 |
Why?
| Plasmapheresis | 1 | 2003 | 11 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 137 | 0.030 |
Why?
| Proteoglycans | 1 | 2003 | 83 | 0.030 |
Why?
| RANK Ligand | 1 | 2004 | 187 | 0.030 |
Why?
| Interleukin-6 | 1 | 2004 | 262 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2006 | 978 | 0.030 |
Why?
| Remission Induction | 2 | 2003 | 208 | 0.030 |
Why?
| Infusions, Intravenous | 2 | 2003 | 213 | 0.030 |
Why?
| NF-kappa B | 1 | 2004 | 315 | 0.020 |
Why?
| Drug Administration Schedule | 2 | 2003 | 370 | 0.020 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.020 |
Why?
| Blood Transfusion, Autologous | 2 | 1992 | 6 | 0.020 |
Why?
| Cell Differentiation | 1 | 2004 | 640 | 0.020 |
Why?
| Graft Rejection | 1 | 2002 | 172 | 0.020 |
Why?
| Colony-Forming Units Assay | 2 | 1992 | 25 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2006 | 1436 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 14 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 19 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 2 | 2003 | 316 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 42 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 63 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 51 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1548 | 0.020 |
Why?
| Biotechnology | 1 | 1999 | 13 | 0.020 |
Why?
| Child, Preschool | 3 | 1994 | 3942 | 0.020 |
Why?
| Immunologic Surveillance | 1 | 1999 | 11 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2010 | 171 | 0.020 |
Why?
| Drug Resistance | 1 | 1998 | 65 | 0.020 |
Why?
| Steroids | 1 | 1998 | 57 | 0.020 |
Why?
| Chromatography, Gas | 1 | 1998 | 15 | 0.020 |
Why?
| Vaccination | 1 | 2010 | 280 | 0.020 |
Why?
| Secondary Prevention | 1 | 1998 | 79 | 0.020 |
Why?
| Neomycin | 1 | 1997 | 4 | 0.020 |
Why?
| Drug Resistance, Microbial | 1 | 1997 | 45 | 0.020 |
Why?
| Rats | 2 | 1998 | 3292 | 0.020 |
Why?
| Leukemia, Erythroblastic, Acute | 1 | 1996 | 5 | 0.020 |
Why?
| Stromal Cells | 1 | 1997 | 75 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 1996 | 18 | 0.020 |
Why?
| Solutions | 1 | 1996 | 25 | 0.020 |
Why?
| Indicators and Reagents | 1 | 1996 | 37 | 0.020 |
Why?
| Clone Cells | 1 | 2006 | 70 | 0.020 |
Why?
| Deoxycytidine | 1 | 2006 | 30 | 0.020 |
Why?
| Temperature | 1 | 1996 | 163 | 0.020 |
Why?
| Genes | 1 | 1995 | 32 | 0.020 |
Why?
| Transduction, Genetic | 1 | 1995 | 46 | 0.020 |
Why?
| In Situ Hybridization | 1 | 1995 | 66 | 0.020 |
Why?
| Chromatography, Affinity | 1 | 1995 | 39 | 0.020 |
Why?
| Fluorouracil | 1 | 1995 | 58 | 0.020 |
Why?
| Genes, Reporter | 1 | 1995 | 88 | 0.020 |
Why?
| Genetic Markers | 1 | 1995 | 104 | 0.020 |
Why?
| Recovery of Function | 1 | 2006 | 191 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1995 | 296 | 0.010 |
Why?
| Lymphocyte Subsets | 1 | 1994 | 14 | 0.010 |
Why?
| Kinetics | 1 | 2006 | 623 | 0.010 |
Why?
| Macaca mulatta | 1 | 1994 | 97 | 0.010 |
Why?
| Propidium | 1 | 1994 | 3 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 1994 | 39 | 0.010 |
Why?
| Immunophenotyping | 1 | 1994 | 105 | 0.010 |
Why?
| Mutation | 1 | 1999 | 1280 | 0.010 |
Why?
| Oligodeoxyribonucleotides | 1 | 1993 | 33 | 0.010 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 154 | 0.010 |
Why?
| Cell Death | 1 | 1994 | 175 | 0.010 |
Why?
| Probability | 1 | 2003 | 164 | 0.010 |
Why?
| Cell Nucleus | 1 | 1994 | 182 | 0.010 |
Why?
| Data Interpretation, Statistical | 1 | 1994 | 163 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 69 | 0.010 |
Why?
| Academic Medical Centers | 1 | 1994 | 149 | 0.010 |
Why?
| Carboplatin | 1 | 1992 | 54 | 0.010 |
Why?
| Multiple Organ Failure | 1 | 2002 | 48 | 0.010 |
Why?
| Neoplasm Metastasis | 1 | 1993 | 232 | 0.010 |
Why?
| Injections, Intravenous | 1 | 1992 | 137 | 0.010 |
Why?
| Statistics as Topic | 1 | 1992 | 89 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 434 | 0.010 |
Why?
| Leukopenia | 1 | 1992 | 8 | 0.010 |
Why?
| Blood Cell Count | 1 | 1992 | 39 | 0.010 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 45 | 0.010 |
Why?
| Doxorubicin | 1 | 2003 | 236 | 0.010 |
Why?
| Linear Models | 1 | 1992 | 279 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 1992 | 415 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2003 | 746 | 0.010 |
Why?
| Pedigree | 1 | 1990 | 119 | 0.010 |
Why?
| HLA Antigens | 1 | 1990 | 52 | 0.010 |
Why?
| Bacterial Infections | 1 | 1991 | 95 | 0.010 |
Why?
| Muscle Cramp | 1 | 1990 | 6 | 0.010 |
Why?
| Mycoses | 1 | 1991 | 155 | 0.010 |
Why?
| Software | 1 | 1992 | 278 | 0.010 |
Why?
| Postoperative Period | 1 | 1990 | 171 | 0.010 |
Why?
| Sepsis | 1 | 2002 | 225 | 0.010 |
Why?
| Disease Progression | 1 | 2003 | 829 | 0.010 |
Why?
| Busulfan | 1 | 1989 | 19 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 1989 | 47 | 0.010 |
Why?
| Hematopoiesis | 1 | 1989 | 72 | 0.010 |
Why?
| Dose-Response Relationship, Radiation | 1 | 1989 | 183 | 0.010 |
Why?
| Glycols | 1 | 1975 | 3 | 0.010 |
Why?
| Quinones | 1 | 1975 | 9 | 0.010 |
Why?
| Hydrocortisone | 1 | 1975 | 110 | 0.010 |
Why?
| Phenols | 1 | 1975 | 82 | 0.010 |
Why?
| Microsomes, Liver | 1 | 1975 | 183 | 0.010 |
Why?
| Fibroblasts | 1 | 1975 | 336 | 0.010 |
Why?
| Cells, Cultured | 1 | 1975 | 1571 | 0.010 |
Why?
| Infant | 1 | 1990 | 3630 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|